MilliporeSigma invests over €500M in technology scale-up
MilliporeSigma, the US and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, has announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately $780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organisation (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years. As per the company, with the addition of Exelead’s leading capabilities and highly experienced team, the Life Science business at MilliporeSigma achieves an important milestone in becoming one of the leading CDMO players in mRNA vaccines and therapeutics, offering an integrated CDMO across the mRNA value chain from pre-clinical to commercial.